Clinical Trials Browser

Phase 1/2 × Neuroblastoma × 30 days × Clear all

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT00911560 2026-06-03

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Phase 1/2 Active not recruiting

374 enrolled

CNS

Neuroblastoma

NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Phase 1/2 Recruiting

289 enrolled

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT06395103 2026-06-01

MK-9999-01A

Phase 1/2 Recruiting

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Phase 1/2 Recruiting

90 enrolled

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Clinical Trials

LUPARPED

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

MK-9999-01A

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma